Ultragenyx Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Ultragenyx Pharma (RARE) Tops Q4 EPS by 3c, Revenues Beat
February 13, 2020 4:04 PM ESTUltragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.62), $0.03 better than the analyst estimate of ($1.65). Revenue for the quarter came in at $35.6 million versus the consensus estimate of $32.15 million.
In 2019 we created a substantial foundation based on the strong launch of Crysvita and the validation of our gene therapy platform across multiple clinical programs, said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of... More
